Recent Updates
Recently added Catalysts
JANX Positive Sentiment

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

Monday, September 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Janux Therapeutics has announced the dosing of the first patient in its Phase 1 clinical trial for JANX013, a bispecific immunotherapy targeting PSMA in metastatic castration-resistant prostate cancer. This trial aims to evaluate the safety and efficacy of JANX013, initially in combination with JANX007. The development marks a significant step forward for the company.

Market Sentiment Analysis

POSITIVE FACTORS

  • First patient dosed in Phase 1 trial indicates progress.
  • Development of JANX013 shows potential for treating mCRPC.
  • Combination therapy with JANX007 may enhance efficacy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+10%
120-day peak, hindsight
Typical move
8.6%
average across 5 past catalysts
Lead asset
JANX007
Phase 1 · Prostate Cancer

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC). The program is initially being developed in combination with JANX007, with the goal of furthe

Frequently Asked Questions

What is JANX013?

JANX013 is a PSMA-targeted bispecific immunotherapy developed by Janux Therapeutics.

What type of cancer is JANX013 targeting?

JANX013 targets metastatic castration-resistant prostate cancer (mCRPC).

What is the goal of the Phase 1 trial?

The Phase 1 trial aims to evaluate the safety and efficacy of JANX013.

Who is the first patient in the trial?

The identity of the first patient has not been disclosed in the announcement.

What is the combination therapy with JANX007?

The trial is initially developing JANX013 in combination with JANX007.

ShareAdd on Google
Tags: JANX Viatris Investor Conferences Healthcare Janux Therapeutics JANX013 mCRPC clinical trial immunotherapy
Last updated: Sep 14, 2026

Biotech snapshot

Cash runway
$971M liquidity · $0M/mo burn
Low dilution risk
Lead asset
JANX007Phase 1
Prostate Cancer →

Catalyst track record

+10%
best trade around JANX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for JANX.

See every catalyst's timing & PoA →